[PDF][PDF] A review of current and emerging therapeutic strategies in multiple sclerosis
MJ Tullman - Am J Manag Care, 2013 - ptce.s3.amazonaws.com
Multiple sclerosis (MS) is a chronic immunemediated disease that potentially requires
symptomatic and disease-modifying therapies. Numerous symptoms (eg, fatigue, spasticity …
symptomatic and disease-modifying therapies. Numerous symptoms (eg, fatigue, spasticity …
[HTML][HTML] Recent developments in multiple sclerosis therapeutics
RI Spain, MH Cameron, D Bourdette - BMC medicine, 2009 - Springer
Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally
considered to be an inflammatory, autoimmune, demyelinating disease of the central …
considered to be an inflammatory, autoimmune, demyelinating disease of the central …
Current and emerging treatment of multiple sclerosis.
FM Hart, J Bainbridge - The American journal of managed care, 2016 - europepmc.org
The treatment of multiple sclerosis (MS) falls into 3 categories: treatment of exacerbations,
slowing disease progression with disease-modifying therapies (DMTs), and symptomatic …
slowing disease progression with disease-modifying therapies (DMTs), and symptomatic …
Established and novel disease‐modifying treatments in multiple sclerosis
AH Cross, RT Naismith - Journal of internal medicine, 2014 - Wiley Online Library
Multiple sclerosis (MS) is a presumed autoimmune disorder of the central nervous system,
resulting in inflammatory demyelination and axonal and neuronal injury. New diagnostic …
resulting in inflammatory demyelination and axonal and neuronal injury. New diagnostic …
Treatment of multiple sclerosis: current concepts and future perspectives
D Buck, B Hemmer - Journal of neurology, 2011 - Springer
Currently, several disease-modifying therapies for the treatment of multiple sclerosis are
established and more are likely to be introduced. These treatment options differ with respect …
established and more are likely to be introduced. These treatment options differ with respect …
[HTML][HTML] Disease-modifying agents in multiple sclerosis
PK Coyle - Annals of Indian Academy of Neurology, 2009 - journals.lww.com
Since 1993, six disease-modifying therapies for multiple sclerosis (MS) have been proven to
be of benefit in rigorous phase III clinical trials. Other agents are also available and are used …
be of benefit in rigorous phase III clinical trials. Other agents are also available and are used …
Update on disease-modifying therapies for multiple sclerosis
DL Vargas, WR Tyor - Journal of Investigative Medicine, 2017 - journals.sagepub.com
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous
system (CNS). It predominantly affects young women and is one of the most common causes …
system (CNS). It predominantly affects young women and is one of the most common causes …
Disease modification in multiple sclerosis: an update
CM Rice - Practical neurology, 2014 - pn.bmj.com
Although there has been unequivocal progress in the development of treatments for multiple
sclerosis over the last 20 years, currently licensed treatments have demonstrated convincing …
sclerosis over the last 20 years, currently licensed treatments have demonstrated convincing …
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm
BAC Cree, J Mares, HP Hartung - Current opinion in neurology, 2019 - journals.lww.com
Current therapeutic landscape in multiple sclerosis: an evol... : Current Opinion in
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …
Highly aggressive multiple sclerosis
JD Bowen - CONTINUUM: Lifelong Learning in Neurology, 2019 - journals.lww.com
PURPOSE OF REVIEW Newly introduced disease-modifying therapies offer greater efficacy
than previous therapies but also have serious side effects. This article reviews factors useful …
than previous therapies but also have serious side effects. This article reviews factors useful …